Login to Your Account



Omeros readies rare clotting disease therapy for phase III

By Michael Fitzhugh
Staff Writer

Tuesday, August 18, 2015

Omeros Corp. shares rose to a record high Tuesday, climbing 72 percent overall to close at $25.03 after the company said OMS721 continued to perform well in a small midstage trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription